FDA Panel Endorses Broader Capivasertib Use in Prostate Cancer
Summary
Agency staff expressed uncertainty over whether PFS benefit was 'clinically meaningful'
Original reporting
Open original sourceAFBytes is a read-only aggregator. Use the original source for full context and complete reporting.